More Frequent Tamoxifen Adjuvant Therapy Results in Sustained Lower Breast Cancer and Overall Mortality Than Aromatase Inhibitors

The 45% higher mortality rate among women aged 70 and over with a history of breast cancer than in the USA urgently needs an explanation. This is hardly explainable by different mammography screening. Endocrine therapy needs to be reviewed, i.e. tamoxifen versus aromatase inhibitors. The latter can provide a biologically plausible explanation for higher mortality due to induced severe estrogen deficiency.